Cite this answer
Ovagen: quick citable summary
Ovagen is listed by PeptaHub as a longevity peptide with a research only legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Ovagen: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/ovagen. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/ovagen.
What is Ovagen?
Ovagen is a synthetic tripeptide (Glu-Asp-Leu) marketed as a Khavinson liver and GI bioregulator. No PubMed-indexed study of it could be located in any species, so its hepatoprotective claims are unverified.
Overview
Ovagen is a synthetic tripeptide (Glu-Asp-Leu, EDL) sold as part of the Khavinson family of cytomaxes and cytogens and marketed as a liver and gastrointestinal bioregulator. Unlike other peptides in that family, it has no located published research: no PubMed-indexed study of EDL in liver or GI tissue was found in animals or humans. The hepatoprotective properties attributed to it are marketing and practice-literature claims, not demonstrated findings.
Mechanism of action
The proposed mechanism is the general Khavinson short-peptide model: di- and tripeptides are taken up by POT-family peptide transporters (PEPT1, PEPT2), reach the nucleus, and interact with DNA to modulate transcription. That transporter and nuclear-penetration work was done on short peptides as a class, not on Ovagen specifically. No published study demonstrating Ovagen's effect on hepatocyte proliferation, fibrosis, or GI mucosal integrity could be located in PubMed, so the liver- and gut-specific mechanism attributed to it is a manufacturer and practice-literature claim rather than a measured result.
Reported study ranges
No reported study ranges available yet.
Research summary
There is essentially no indexed research on Ovagen. Searches of PubMed return no study of the Glu-Asp-Leu (EDL) peptide in liver or gastrointestinal tissue, in animals or humans. Claims about hepatocyte regeneration, fibrosis reduction and mucosal protection circulate in supplier and Russian practice literature but are not backed by any located publication. Treat Ovagen as an unstudied compound: the general Khavinson short-peptide framework may apply to it in principle, but no organ-specific effect has been demonstrated.[1]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Ovagen for synergistic effects.
Legal status
Not FDA-approved. Developed and commercialized in Russia as a cytogen bioregulator supplement. Available in Western markets as a research chemical. Not approved for therapeutic human use outside Russia.
Sourcing & access
Research compound
Ovagen is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Ovagen is a synthetic tripeptide (Glu-Asp-Leu, EDL) sold as part of the Khavinson cytogen range and marketed for liver and gastrointestinal support. No published study of it could be located, so that positioning rests on marketing rather than evidence.
This is not established. The proposed model is the one used for Khavinson short peptides generally: uptake via PEPT1/PEPT2 transporters, nuclear entry, and interaction with DNA to modulate transcription. That work was done on short peptides as a class. Nothing specific to Ovagen's action in liver or gut tissue has been published.
Unknown. There are no published safety data of any kind for Ovagen, in humans or animals. Mild injection site irritation is the only effect commonly reported anecdotally. It is not FDA-approved.
Nothing that is published. Searches of PubMed return no study of the EDL peptide in liver or gastrointestinal tissue. Claims about hepatocyte proliferation, fibrosis reduction and mucosal protection appear in supplier material without a traceable source study behind them.